On April 3, as part of the “Au cœur des sites” (At the heart of our sites) program organized by G5 Santé, a group of France’s key healthcare industries, patient organization representatives were invited to visit our Paris-Saclay R&D Institute. The event was designed to give the organizations greater insight into the commitment of G5 Santé companies to ensuring access to medicines for patients throughout France. It was also a great opportunity to highlight our R&D! 

Six representatives from four patient organizations visited our Institute in Paris-Saclay: Alliance du Cœur, Ellye, AVEC (Association Vie Et Cœur) and Espoir Pancréas.

The program was tailor-made to showcase our patient involvement in R&D programs, the work of the Institute’s researchers, and our integrated CSR approach at the Saclay site. Guillaume Molinier, from Alliance du Cœur, emphasized the importance of visiting sites and meeting employees. “Meeting researchers means getting to know the people who work day in and day out to discover therapeutic solutions. The human element behind the company is essential,” he said.

Patients also enjoyed the many opportunities for interaction, including educational sessions on the Group’s strategy, with a special focus on oncology and rare diseases. Annie Charrette and Philippe Francois-Steininger from Espoir Pancréas were particularly impressed: “We had the opportunity to learn more about Servier R&D. Paris-Saclay’s scientific community is a real asset, not only for G5 Santé, but also for France as a whole.” 

« Patients’ opinions and needs must be shared and taken into account in the decision-making process, in industry, healthcare systems and any other environment and ecosystem that affects them. Valuing their opinions and contributions, as Servier does, is essential so that research progresses in the right direction. »

Steven Macari, AVEC (Association Vie Et Cœur)

These views are shared by our teams :

« At Paris-Saclay, we are building more agile, more open, and ever more patient-centric R&D to accelerate the discovery of innovative therapeutic solutions. This inevitably involves integrating the patient voice into our R&D processes. Today’s event is just one example. »

Marta Garcia, Chief Patient Officer R&D

Le G5 santé, the voice of the French healthcare industry

G5 santé is a think-tank bringing together the heads of France’s leading healthcare and life sciences companies (bioMérieux, Guerbet, Ipsen, LFB, Pierre Fabre, Sanofi, Servier and Théa). These companies have chosen France as a strategic base for their international development and have made R&D and production their top priorities. For the third consecutive year, from March 11 to April 3, 2024, the eight G5 Santé companies opened the doors of a dozen production and research sites to representatives of partner patient organizations, with the aim of continuing a lasting and fruitful dialogue with healthcare users.